信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

休市中 12-05 16:09:08

92.000

-1.550

-1.66%

最高94.850	最低90.250	成交量3,389万
今开93.700	昨收93.550	日振幅4.92%
总市值1,583亿	流通市值1,583亿	总股本17.21亿
成交额31.11亿	换手率1.97%	流通股本17.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":92,"timestamp":1764922148002,"preClose":93.55,"halted":0,"volume":33885838,"delay":0,"floatShares":1721000000,"shares":1721000000,"eps":-0.06403918179270399,"marketStatus":"休市中","change":-1.55,"latestTime":"12-05 16:09:08","open":93.7,"high":94.85,"low":90.25,"amount":3111488199,"amplitude":0.049172,"askPrice":92,"askSize":117000,"bidPrice":91.95,"bidSize":45500,"shortable":3,"etf":0,"ttmEps":0.7430421790835628,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":7,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":93.55,"openAndCloseTimeList":[[1764898200000,1764907200000],[1764910800000,1764921600000]],"volumeRatio":4.247530345051284,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.4412,"impliedVolPercentile":0.1016},"requestUrl":"/m/hq/s/01801/tweets","defaultTab":"tweets","newsList":[{"id":"1155392565","title":"信达生物宣布七种创新药物入选中国国家医保药品目录，包括Tyvyt新适应症和Sycume","url":"https://stock-news.laohu8.com/highlight/detail?id=1155392565","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155392565?lang=zh_cn&edition=full","pubTime":"2025-12-07 11:41","pubTimestamp":1765078874,"startTime":"0","endTime":"0","summary":"信达生物宣布七种创新药物入选中国国家医保药品目录，包括Tyvyt新适应症和Sycume。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0455707207.USD","BK1161","LU2097828714.EUR","LU1969619763.USD","LU2488822045.USD","LU2097828805.USD","LU2097828631.EUR","LU2328871848.SGD","BK1589","LU0502904849.HKD","BK1583","LU2097828557.USD","01801","NUVB","LU2242644610.SGD","HK0000165453.HKD","LU2097828474.EUR"],"gpt_icon":0},{"id":"2589892558","title":"信达生物(01801)授出1.5万份购股权及14.82万股受限制股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2589892558","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589892558?lang=zh_cn&edition=full","pubTime":"2025-12-05 20:33","pubTimestamp":1764938003,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物(01801)公布，于2025年12月5日，公司根据2024年股份计划的条款向3名承授人授出1.5万份购股权，及向29名承授人授出14.82万股受限制股份，惟须待承授人接纳。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信达生物(01801)授出1.5万份购股权及14.82万股受限制股份","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828631.EUR","BK1589","LU1969619763.USD","LU0455707207.USD","LU2097828474.EUR","LU2328871848.SGD","LU2097828805.USD","BK1161","LU2097828714.EUR","HK0000165453.HKD","BK1583","LU2242644610.SGD","LU2097828557.USD","LU0502904849.HKD","LU2488822045.USD","01801"],"gpt_icon":0},{"id":"2589818225","title":"12月5日港股药品及生物科技行业沽空数据盘点，信达生物、翰森制药、药明康德沽空金额位居行业前三","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818225","media":"证券之星APP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589818225?lang=zh_cn&edition=full","pubTime":"2025-12-05 18:06","pubTimestamp":1764929210,"startTime":"0","endTime":"0","summary":"证券之星消息，12月5日港交所披露数据显示，当日港股药品及生物科技行业的159只个股中有82只被沽空，总沽空股数为9183.67万股，总沽空金额为27.5亿元（港元），而当日药品及生物科技行业的总成交金额为126.22亿元（港元），沽空比例为21.79%。当日药品及生物科技行业总体涨0.07%。从沽空金额来看，信达生物、翰森制药、药明康德沽空金额位居行业前三，分别为11.43亿港元、3.46亿港元、2.49亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205181415952ca0ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205181415952ca0ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","LU0502904849.HKD","LU0455707207.USD","BK1576","LU0708995583.HKD","LU2488822045.USD","LU1969619763.USD","LU2097828714.EUR","03692","LU1046422090.SGD","BK1141","LU2125910500.SGD","02359","LU2045819591.USD","BK1191","01801","LU2097828805.USD","LU2097828474.EUR","LU0320764599.SGD","HK0000165453.HKD","LU2328871848.SGD","LU2242644610.SGD","LU2097828557.USD","LU2097828631.EUR","BK1583","LU0052750758.USD","BK1161"],"gpt_icon":0},{"id":"2589581541","title":"多个减重药物迎来新进展，涉及中国生物制药、信达生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2589581541","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589581541?lang=zh_cn&edition=full","pubTime":"2025-12-05 15:58","pubTimestamp":1764921480,"startTime":"0","endTime":"0","summary":"全球超6.5亿人受肥胖困扰，中国减肥药市场潜力巨大，GLP-1类药物市场增速超全球平均。国内药企积极布局并实现突破，12月4日，中国生物制药自主研发的TQF3250胶囊临床试验申请获中美批准，该药是口服小分子偏向型GLP-1受体激动剂，有望实现更优血糖与体重控制，降低副作用，提升用药便利性。11月20日，信达生物宣布玛仕度肽III期临床研究达成主要终点，25日其高剂量9mg上市申请获受理，该药可显著减轻体重、改善代谢指标，且耐受性和安全性良好。此外，常山药业、派格生物等也有GLP-1类药物处于上市申请阶段。国内药企的突破得益于政策、研发和市场需求的驱动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205161052a4ce58cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205161052a4ce58cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1589","LU2242644610.SGD","IE00BZ08YR35.GBP","BK1583","LU2097828474.EUR","01801","LU2097828631.EUR","LU2097828714.EUR","IE00BZ08YS42.EUR","BK1161","LU2097828557.USD","LU2097828805.USD","LU0455707207.USD","BK1191","LU0502904849.HKD","HK0000165453.HKD","LU2488822045.USD","IE00BZ08YT58.USD","LU2328871848.SGD","01177","BK1515","LU1969619763.USD"],"gpt_icon":0},{"id":"2589856915","title":"智通港股通持股解析|12月5日","url":"https://stock-news.laohu8.com/highlight/detail?id=2589856915","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589856915?lang=zh_cn&edition=full","pubTime":"2025-12-05 08:30","pubTimestamp":1764894602,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，根据2025年12月4日披露数据，中国电信、绿色动力环保、昊天国际建投位居港股通持股比例前3位，分别为72.75%、69.12%、68.59%。此外，阿里巴巴－W、美团-W、泡泡玛特在最近有统计数据的5个交易日内，持股额增幅最大，分别为+36.91亿元、+19.48亿元、+12.39亿元;紫金矿业、中芯国际、中国移动在最近有统计数据的5个交易日内，持股额减幅最大，分别为-11.62亿元、-9.24亿元、-4.58亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01108","01635","01088","00939","01456","03033","02238","03958","80883","HMTD.SI","01065","01288","01801","02202","LNVGY","06869","02899","01138","00956","03143","000002","601318","00941","PAImain","01341","80992","00992","02359","PNGAY","01330","01375","00728","03690","00762","01798","00883","02318","82318","03145","03968","MPNGY","09992","01776","03678","LU0326950275.SGD","02628","HPAD.SI"],"gpt_icon":1},{"id":"1118331550","title":"信达生物宣布与武田关闭全球战略合作伙伴关系，聚焦下一代免疫肿瘤学与抗体药物偶联物治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1118331550","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118331550?lang=zh_cn&edition=full","pubTime":"2025-12-05 07:39","pubTimestamp":1764891551,"startTime":"0","endTime":"0","summary":"信达生物宣布与武田关闭全球战略合作伙伴关系，聚焦下一代免疫肿瘤学与抗体药物偶联物治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828631.EUR","HK0000165453.HKD","LU2097828805.USD","LU2328871848.SGD","BK1161","LU1969619763.USD","LU2488822045.USD","LU2097828474.EUR","LU0502904849.HKD","LU2097828557.USD","BK1583","LU2242644610.SGD","LU2097828714.EUR","LU0455707207.USD","01801","BK1589"],"gpt_icon":0},{"id":"2589685310","title":"信达生物(01801)完成与武田制药的全球战略合作及根据一般授权发行691.38万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2589685310","media":"智通财经","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589685310?lang=zh_cn&edition=full","pubTime":"2025-12-05 07:15","pubTimestamp":1764890112,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，内容有关信达生物与武田制药达成全球战略合作，许可、选择权及合作协议及股份发行协议各自的所有先决条件均已达成或获豁免(如适用)。于股份发行协议完成后，公司向认购人配发及发行691.38万股股份，占发行认购股份后公司已发行股本的约0.40%。配发及发行认购股份的所得款项总额约为7.78亿港元，而所得款项净额约为7.77亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377949.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2242644610.SGD","LU2488822045.USD","BK1589","LU0502904849.HKD","LU2097828474.EUR","LU2097828557.USD","HK0000165453.HKD","LU0455707207.USD","LU2097828631.EUR","LU2097828805.USD","01801","LU2097828714.EUR","BK1583","TAK","BK4007","LU1969619763.USD","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2588688188","title":"拜耳降价，齐鲁秒跟，却打中了绿叶制药的“七寸”","url":"https://stock-news.laohu8.com/highlight/detail?id=2588688188","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588688188?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:41","pubTimestamp":1764848486,"startTime":"0","endTime":"0","summary":"但拜耳和齐鲁这轮降价，却正好打中了 绿叶制药 的七寸。11月26日， 绿叶制药 子公司 博安生物 的阿柏西普生物类似药获批上市，成为国内第二个获批的产品。齐鲁制药是最先成功的。2023年12月，齐鲁制药阿柏西普生物类似药获批上市。2024年8月，齐鲁拿下了雷珠单抗国内首个生物类似药。9月30日，RC28已经申报上市，用于治疗糖尿病黄斑水肿，预计不久后就将加入眼底病用药的“战场”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204194908a4cc968e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204194908a4cc968e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09995","02186","01801","BK1606","LU2328871848.SGD","BK1583","BK1191","LU1969619763.USD","BK1161"],"gpt_icon":0},{"id":"2588836158","title":"每日卖空追踪 | 信达生物 12月04日卖空量成交70.85万股，卖空比例为9.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588836158","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588836158?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:30","pubTimestamp":1764837026,"startTime":"0","endTime":"0","summary":"信达生物北京时间12月04日，涨1.91%，卖空量成交70.85万股，较上一交易日减少57.22%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163316a72357f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163316a72357f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828557.USD","HK0000165453.HKD","LU2097828714.EUR","BK1161","LU2328871848.SGD","LU2488822045.USD","LU2097828474.EUR","BK1583","BK1589","LU1969619763.USD","LU2242644610.SGD","LU0455707207.USD","LU2097828631.EUR","LU0502904849.HKD","01801","LU2097828805.USD"],"gpt_icon":0},{"id":"2588076380","title":"【券商聚焦】中泰国际：北京与上海相继出台政策支持创新医疗器械的开发 料有利于创新医疗器械板块发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2588076380","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588076380?lang=zh_cn&edition=full","pubTime":"2025-12-04 09:04","pubTimestamp":1764810245,"startTime":"0","endTime":"0","summary":"医疗器械板块上涨，该机构估计是由于北京与上海相继出台政策支持创新医疗器械开发。北京出台《北京市促进医疗器械产业高质量发展若干措施》，提出多条举措支持创新器械的临床研发、注册上市、销售推广、产业链发展和出海。该机构认为以上政策有利于创新医疗器械板块的发展，但港股大型创新医疗器械生产商不多，该机构对传统医疗器械生产商的2025年业绩偏谨慎。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970861","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","BK1141","LU0516423091.SGD","LU0819121731.USD","01066","HK0000165453.HKD","LU0307460666.USD","BK1191","LU0456827905.SGD","159883","02359","LU2039709279.SGD","LU0051755006.USD","LU0140636845.USD","LU0823426308.USD","09996","09997","LU0359202008.SGD","LU2488822045.USD","LU3063872942.SGD","LU2125910500.SGD","IE00BZ08YT58.USD","BK1583","LU2328871848.SGD","LU0708995583.HKD","01177","LU1880383366.USD","LU2097828474.EUR","LU2097828631.EUR","LU0348735423.USD","LU2097828805.USD","LU2242644610.SGD","SG9999002463.SGD","LU0516423174.USD","LU0823426480.USD","03692","LU0348825331.USD","LU0856984785.SGD","LU2097828714.EUR","LU1969619763.USD","LU2045819591.USD","BK1100","LU0173614495.USD","LU0456846285.SGD","02269","BK1161","IE00B0JY6N72.USD","01801","LU0359201612.USD","BK1574"],"gpt_icon":0},{"id":"2588073495","title":"智通港股通持股解析|12月4日","url":"https://stock-news.laohu8.com/highlight/detail?id=2588073495","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588073495?lang=zh_cn&edition=full","pubTime":"2025-12-04 08:30","pubTimestamp":1764808201,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，根据2025年12月3日披露数据，中国电信、绿色动力环保、大众公用位居港股通持股比例前3位，分别为72.68%、69.12%、69.03%。此外，阿里巴巴－W、美团-W、泡泡玛特在最近有统计数据的5个交易日内，持股额增幅最大，分别为+33.29亿元、+13.19亿元、+10.60亿元;紫金矿业、中芯国际、联想集团在最近有统计数据的5个交易日内，持股额减幅最大，分别为-8.61亿元、-8.15亿元、-4.30亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02328","00939","00992","03145","HPAD.SI","PNGAY","03678","02318","HMTD.SI","01065","80883","03143","01456","01138","01288","06969","MPNGY","03033","01801","02899","01798","PAImain","00728","09992","601318","LNVGY","LU0164865239.USD","01375","01330","01341","03958","00941","00762","01088","00956","01108","000002","03968","02628","80992","82318","01776","03690","02238","01635","06869"],"gpt_icon":1},{"id":"2588003899","title":"12月3日港股药品及生物科技行业沽空数据盘点，三生制药、信达生物、百济神州沽空金额位居行业前三","url":"https://stock-news.laohu8.com/highlight/detail?id=2588003899","media":"证券之星APP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588003899?lang=zh_cn&edition=full","pubTime":"2025-12-03 18:06","pubTimestamp":1764756374,"startTime":"0","endTime":"0","summary":"当日药品及生物科技行业总体跌1.74%。从沽空金额来看，三生制药、信达生物、百济神州沽空金额位居行业前三，分别为2.37亿港元、1.53亿港元、9825.69万港元。从沽空比例偏离度来看，乐普生物-B、思派健康、信达生物沽空比例偏离度位居行业前三，分别为306.25%、195.17%、192.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120318154995289c94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120318154995289c94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU2097828805.USD","LU2488822045.USD","LU2242644610.SGD","HK0000165453.HKD","BK1588","01530","LU2097828714.EUR","LU0502904849.HKD","LU2097828631.EUR","BK1589","LU1719994722.HKD","LU2097828557.USD","BK1583","BK1500","LU2097828474.EUR","LU1251922891.USD","01801","LU0307460666.USD","BK1161","LU1770034418.SGD","06160","LU2328871848.SGD","LU1303224171.USD","LU0588546209.SGD","LU0455707207.USD","BK1593"],"gpt_icon":0},{"id":"2588038980","title":"信达生物12月03日遭主力抛售2451.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588038980","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588038980?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:15","pubTimestamp":1764749757,"startTime":"0","endTime":"0","summary":"12月03日, 信达生物股价跌2.18%，报收91.80元，成交金额7.6亿元，换手率0.48%，振幅3.78%，量比0.88。信达生物今日主力资金净流出2451.7万元，连续4日净流出，上一交易日主力净流出136.1万元。该股近5个交易日下跌3.85%，主力资金累计净流出5598.5万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入2.7亿元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203162133a7210641&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203162133a7210641&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","LU0455707207.USD","BK1161","01801","BK1583","BK1589","LU2097828474.EUR","LU2097828805.USD","LU2242644610.SGD","LU2097828557.USD","LU2488822045.USD","LU0502904849.HKD","LU1969619763.USD","LU2097828714.EUR","HK0000165453.HKD","LU2097828631.EUR"],"gpt_icon":0},{"id":"2588343016","title":"创新药概念持续调整 歌礼制药(01672)跌逾1成 机构指仿制药下降趋势无法避免 影响制药行业","url":"https://stock-news.laohu8.com/highlight/detail?id=2588343016","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588343016?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:08","pubTimestamp":1764749332,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念持续调整，临近收盘，歌礼制药(01672)跌11.1%，圣诺医药(02257)跌10.9%，信达生物(01801)跌2.72%，药明生物(02269)跌1.8%，百济神州(06160)跌1.35%。国元国际指出，医药行业目前已经进行了十一批国家药品集中带量采购以及多轮医保谈判，随着药品带量采购的常态化进行，仿制药行业的下降趋势无法避免，对制药行业有一定的影响。2025年1-9月医药制造业实现营业收入同比略下降2.0%，利润总额同比略下降0.7%，整体比较平稳。受集采、医保谈判的影响，仿制药的前景平淡，未来行业的发展需要创新药来推动增长。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970832","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423174.USD","LU1688375341.USD","LU2097828805.USD","LU0327786744.USD","LU0140636845.USD","LU2097828714.EUR","LU1794554557.SGD","LU2488822045.USD","LU0979878070.USD","LU0052750758.USD","159992","LU1242518857.USD","LU1720050803.USD","LU1770034418.SGD","BK1161","LU0588546209.SGD","02257","LU0516422440.USD","LU3063872942.SGD","LU0819121731.USD","06160","06978","LU1242518931.SGD","02269","LU1303224171.USD","01801","BK1576","LU0455707207.USD","LU0516422952.EUR","LU0417516738.SGD","SG9999002562.SGD","BK1610","LU0181495838.USD","LU0051755006.USD","BK1141","LU0039217434.USD","IE00B0JY6N72.USD","LU0823426308.USD","LU2097828631.EUR","LU2097828474.EUR","LU2039709279.SGD","BK1521","LU0417516902.SGD","LU0502904849.HKD","01477","LU1880383366.USD","HK0000165453.HKD","01672","LU0307460666.USD","BK1191"],"gpt_icon":0},{"id":"2588099335","title":"【券商聚焦】国信证券：港股短线的调整为2026年赢得空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2588099335","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588099335?lang=zh_cn&edition=full","pubTime":"2025-12-03 11:09","pubTimestamp":1764731351,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国信证券研报指，港股短线的调整为2026年赢得空间。但站在布局明年的角度，有不少乐观的理由，包括：1、美联储持续降息将带来流动性的逐步宽松；2、AI 的进步值得期待，26 年有望更加广泛的 AI 应用推出；3、汽车、半导体明年依然有较好的利润增长；4、外卖战有望在 26 年的某个时间趋缓；5、十五五规划落地带来的积极影响。美元指数将在26年初期持续走弱，这有利于新兴市场的估值修复。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970805","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0469268626.HKD","002736","LU0315179316.USD","LU0862451753.SGD","LU1794554557.SGD","HK0000320223.HKD","LU2039709279.SGD","00325","LU0634319403.HKD","LU0871576103.HKD","IE0032834883.USD","LU1152091168.USD","01177","BK1609","02121","LU0051755006.USD","LU2399975544.HKD","LU1303224171.USD","BK1163","01318","HK0000306701.USD","LU1226287875.USD","IE00B0169L03.USD","LU0501845795.SGD","IE00B5MMRT66.SGD","06181","BK1583","IE00B97KM107.HKD","LU0611395673.USD","LU1008478684.HKD","09999","LU0633140560.USD","LU1251922891.USD","01801","LU0052750758.USD","LU0307460666.USD","LU1961090484.USD","LU0588546209.SGD","LU1688375341.USD","LU0039217434.USD","LU2476274720.SGD","LU0106959298.USD","IE0008369823.USD","LU0049853897.USD","LU0456827905.SGD","LU0320764599.SGD","01093","LU0348825331.USD"],"gpt_icon":1},{"id":"2588503713","title":"信达生物12月02日遭主力抛售136.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588503713","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588503713?lang=zh_cn&edition=full","pubTime":"2025-12-02 16:15","pubTimestamp":1764663339,"startTime":"0","endTime":"0","summary":"12月02日, 信达生物股价跌1.00%，报收93.85元，成交金额6.3亿元，换手率0.39%，振幅2.22%，量比0.63。信达生物今日主力资金净流出136.1万元，连续3日净流出，上一交易日主力净流出5206.3万元。该股近5个交易日下跌0.43%，主力资金累计净流入3194.4万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入3.1亿元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202161836952650a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202161836952650a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828474.EUR","01801","LU2097828631.EUR","LU2328871848.SGD","LU0455707207.USD","BK1583","HK0000165453.HKD","LU1969619763.USD","LU2097828557.USD","LU2488822045.USD","BK1589","BK1161","LU2097828714.EUR","LU0502904849.HKD","LU2097828805.USD","LU2242644610.SGD"],"gpt_icon":0},{"id":"2588746081","title":"新药获批资本市场反应平淡，管线＂断档＂57％，信达生物＂创新＂故事讲不下去了？｜创新药观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2588746081","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588746081?lang=zh_cn&edition=full","pubTime":"2025-12-02 13:43","pubTimestamp":1764654211,"startTime":"0","endTime":"0","summary":"信达生物近期迎来研发突破，一款自主原研新药获批上市。然而，这一利好消息并未转化为资本市场的积极反馈，资本市场反应平淡，与研发成果形成鲜明反差，引发业内对其发展现状的关注。目前，信达生物的核心产品或面临增长瓶颈，传统优势领域受政策影响增速放缓；同时，研发管线隐忧渐显，在研项目推进不及预期，部分核心产品还将面临激烈的市场竞争，管线“断档”风险成为制约公司未来增长的潜在因素。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512023580258456.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023580258456.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","LU2097828714.EUR","06978","LU2097828631.EUR","BK1574","LU2097828474.EUR","LU2097828557.USD","159992","LU0502904849.HKD","01801","HK0000165453.HKD","BK1161","LU2488822045.USD","LU2242644610.SGD","LU2097828805.USD","LU2328871848.SGD","LU1969619763.USD","LU0455707207.USD","BK1589"],"gpt_icon":0},{"id":"2588431377","title":"港股医药投资迎新篇章！恒生生物科技ETF富国今日盛大首发！","url":"https://stock-news.laohu8.com/highlight/detail?id=2588431377","media":"全景网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588431377?lang=zh_cn&edition=full","pubTime":"2025-12-01 11:04","pubTimestamp":1764558240,"startTime":"0","endTime":"0","summary":"近期，医药生物板块利好密集释放。与此同时，港股医药投资生态亦迎重磅升级——恒生生物科技指数期货已于11月28日正式上市交易。在此双重利好驱动下，富国基金顺势推出恒生生物科技ETF富国，该基金于今日重磅首发，为投资者提供了高效布局港股生物科技龙头的前沿工具。恒生生物科技ETF富国凭借其对核心资产的精准覆盖、科学的指数编制与显著的估值优势，为投资者提供了把握产业变革机遇的高效工具。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201110535a71bd9cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201110535a71bd9cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828714.EUR","LU1969619763.USD","LU2242644610.SGD","01801","06160","LU2097828631.EUR","LU2097828474.EUR","BK1574","BK1583","LU2097828805.USD","LU2488822045.USD","HK0000165453.HKD","BK1589","02269","LU2097828557.USD","LU0455707207.USD","BK1161","06978","LU0502904849.HKD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2588156743","title":"医药生物行业周报：关注血液净化器械领域国产替代机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2588156743","media":"光大证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588156743?lang=zh_cn&edition=full","pubTime":"2025-12-01 00:00","pubTimestamp":1764518400,"startTime":"0","endTime":"0","summary":"血液净化类高值医用耗材市场，进口产品占据70%以上的市场份额。透析机和透析器技术壁垒相对较高，我国市场仍是外资主导；透析管路国内产品的市占率接近50%，透析粉/液已基本实现进口替代。建议关注国产血液净化器械领域龙头公司山外山、威高血净、宝莱特、健帆生物、三鑫医疗、天益医疗等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201105635a71bd540&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201105635a71bd540&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828805.USD","LU2488822045.USD","06996","BK1161","LU0455707207.USD","LU2328871848.SGD","LU2097828631.EUR","LU2097828474.EUR","LU2097828714.EUR","01801","HK0000165453.HKD","LU2242644610.SGD","LU2097828557.USD","BK1589","LU1969619763.USD","BK1583","LU0502904849.HKD"],"gpt_icon":0},{"id":"2587766587","title":"信达生物开足马力","url":"https://stock-news.laohu8.com/highlight/detail?id=2587766587","media":"药械Talks","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587766587?lang=zh_cn&edition=full","pubTime":"2025-11-29 07:26","pubTimestamp":1764372403,"startTime":"0","endTime":"0","summary":"从上述种种情况来看，信达生物确实在猛踩油门、开足马力，冲击“2027年产品收入达200亿元”的宏伟目标。2025年上半年，信达生物实现总收入59.53亿元，归母净利润达8.34亿元，确实距离目标越来越近了。资本市场也给予了正向反馈：2025年至今，信达生物股价累计涨幅达到157%，总市值超过1600亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251129072913a4c13c37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251129072913a4c13c37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2242644610.SGD","BK1589","LU2328871848.SGD","LU2097828714.EUR","01801","LU1969619763.USD","LU2097828474.EUR","LU2097828805.USD","LU2097828557.USD","HK0000165453.HKD","LU2488822045.USD","BK1161","LU0455707207.USD","LU0502904849.HKD","BK1583","LU2097828631.EUR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":0.0449},{"period":"3month","weight":-0.1077},{"period":"6month","weight":0.2577},{"period":"1year","weight":1.4436},{"period":"ytd","weight":1.5137}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.0058},{"period":"3month","weight":0.0262},{"period":"6month","weight":0.0964},{"period":"1year","weight":0.3336},{"period":"ytd","weight":0.3004}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.056031},{"month":2,"riseRate":0.714286,"avgChangeRate":0.11927},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.021767},{"month":4,"riseRate":0.714286,"avgChangeRate":0.040816},{"month":5,"riseRate":0.428571,"avgChangeRate":0.027398},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.044947}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}